Cargando…

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors

Immuno-oncology is an ever growing field that has seen important progress across the spectrum of cancers. Responses can be deep and durable. However, as only a minority of patients respond to checkpoint inhibition, predictive biomarkers are needed. Cancer is a genetic disease arising from the accumu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedlaender, Alex, Nouspikel, Thierry, Christinat, Yann, Ho, Liza, McKee, Thomas, Addeo, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028749/ https://www.ncbi.nlm.nih.gov/pubmed/32117779 http://dx.doi.org/10.3389/fonc.2020.00142

Ejemplares similares

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014
por: Munk, Niki, et al.
Publicado: (2016)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
por: Miao, Ya-Ru, et al.
Publicado: (2022)

Intratumor heterogeneity of driver mutations and TMB distribution in 30 early-stage LUAD patients with multiple lesions
por: Qiu, Yuan, et al.
Publicado: (2022)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
por: Qiu, Ping, et al.
Publicado: (2019)

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC
por: Křížová, Ľudmila, et al.
Publicado: (2022)

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting
por: Zhang, Chenyue, et al.
Publicado: (2021)

ecTMB: a robust method to estimate and classify tumor mutational burden
por: Yao, Lijing, et al.
Publicado: (2020)

Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
por: Zhao, Yan, et al.
Publicado: (2023)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

The Greater Value of the CONSORT Statement Guidelines: Guideposts for Designing and Reporting all TMB Research
por: Porcino, Antony J.
Publicado: (2012)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
por: Hodi, F. Stephen, et al.
Publicado: (2021)

Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB
por: Li, Mingyu, et al.
Publicado: (2023)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

TMB-Hunt: a web server to screen sequence sets for transmembrane β-barrel proteins
por: Garrow, Andrew G., et al.
Publicado: (2005)

The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Nan, Zhang, et al.
Publicado: (2021)

A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response
por: Weir, William H., et al.
Publicado: (2022)

TMB-Hunt: An amino acid composition based method to screen proteomes for beta-barrel transmembrane proteins
por: Garrow, Andrew G, et al.
Publicado: (2005)

No-U-turn sampling for fast Bayesian inference in ADMB and TMB: Introducing the adnuts and tmbstan R packages
por: Monnahan, Cole C., et al.
Publicado: (2018)

Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma
por: Gu, Weiquan, et al.
Publicado: (2020)

1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants
por: Towner, William, et al.
Publicado: (2020)

Ground state and stability of the fractional plateau phase in metallic Shastry–Sutherland system TmB(4)
por: Orendáč, Matúš, et al.
Publicado: (2021)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
por: McCann, Katy, et al.
Publicado: (2022)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
por: Wang, Hui, et al.
Publicado: (2022)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
por: Cui, Shengjin, et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Rotating magnetocaloric effect and unusual magnetic features in metallic strongly anisotropic geometrically frustrated TmB(4)
por: Orendáč, Matúš, et al.
Publicado: (2018)

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications
por: Saeed, Anwaar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9qc4s4tkc3khir9lj6kttl3ocp